Identification of a graft versus host disease-associated human minor histocompatibility antigen

Science
J M den HaanV H Engelhard

Abstract

Minor histocompatibility antigen disparities between human leukocyte antigen (HLA)-matched bone marrow donors and recipients are a major risk factor for graft versus host disease (GVHD). An HLA-A2.1-restricted cytotoxic T cell clone that recognized the minor histocompatibility antigen HA-2 was previously isolated from a patient with severe GVHD after HLA-identical bone marrow transplantation. The HLA-A2.1-bound peptide representing HA-2 has now been identified. This peptide appears to originate from a member of the non-filament-forming class I myosin family. Because HA-2 has a phenotype frequency of 95 percent in the HLA-A2.1-positive population, it is a candidate for immunotherapeutic intervention in bone marrow transplantation.

References

Feb 1, 1992·International Immunology·M SekimataM Takiguchi
Aug 23, 1990·Nature·B PérarnauF A Lemonnier
Sep 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·D F HuntC R Hauer
Jun 1, 1970·Transplantation·M M Bortin
Nov 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·R A HendersonV H Engelhard
Jul 5, 1994·Proceedings of the National Academy of Sciences of the United States of America·W M BementM S Mooseker
Feb 1, 1993·Current Opinion in Cell Biology·M A Titus
Mar 1, 1993·European Journal of Immunology·M de BuegerE Goulmy
Apr 1, 1993·Current Biology : CB·M Mooseker

❮ Previous
Next ❯

Citations

May 13, 1999·Mass Spectrometry Reviews·A de Jong
Jan 1, 1996·Springer Seminars in Immunopathology·V H Engelhard
Nov 15, 2002·International Journal of Hematology·Stanley R RiddellE H Warren
May 12, 2005·Cancer Immunology, Immunotherapy : CII·Johannes ScheteligMartin Bornhäuser
Oct 1, 1995·Current Opinion in Immunology·M Theobald
Mar 1, 1996·Molecular Medicine Today·G E Sale
Jan 1, 1996·Molecular Medicine Today·M P Davenport, A V Hill
Apr 23, 2004·Trends in Immunology·Eric SpieringsEls Goulmy
Jun 22, 1999·Leukemia Research·M A RoskrowM K Brenner
Mar 24, 1998·Immunology Today·C PerreaultC Fortin
Jul 1, 1997·Human Immunology·N J PoindexterT Mohanakumar
Dec 1, 1995·Blood Reviews·H E HeslopM K Brenner
Mar 29, 2001·Experimental Hematology·H GokerN J Chao
Jul 5, 2003·Experimental Hematology·Imad A Tabbara, Richard M Ingram
Sep 10, 2003·Experimental Hematology·J H Frederik FalkenburgRoel Willemze
Dec 24, 2002·Current Opinion in Immunology·Ross M KedlPhilippa Marrack
Oct 1, 1996·Current Opinion in Immunology·C J MeliefW M Kast
Feb 1, 1996·Current Opinion in Immunology·E Goulmy
Nov 22, 1997·Current Opinion in Immunology·E Simpson, D Roopenian
Dec 10, 1999·Journal of the American Society for Mass Spectrometry·M B Barroso, A P de Jong
Dec 21, 2002·Immunological Reviews·Derry RoopenianAaron Brown
Dec 1, 2009·Bone Marrow Transplantation·S PaczesnyP Reddy
Feb 9, 2011·Immunology and Cell Biology·Marie Bleakley, Stanley R Riddell
Dec 22, 2004·Nature Immunology·Eric Vivier, Bernard Malissen
Aug 1, 1997·Nature Medicine·D Pardoll
Apr 18, 2007·Nature Reviews. Immunology·Warren D Shlomchik
Jul 6, 2007·Leukemia·J H Kessler, C J M Melief
Jul 27, 2001·British Journal of Haematology·R E ClarkUNKNOWN Chronic Leukaemia Working Party of the European Group of Blood and Bone Marrow Transplantation

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.